Bionomics Ltd

Bionomics Ltd. is a clinical stage biopharmaceutical company. It engages in the development of novel drug candidates focused on the treatment of serious central nervous system disorders. The company was founded in 1996 and is headquartered in Eastwood, Australia.

Bionomics Ltd. is a clinical stage biopharmaceutical company, which develops novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need. Its lead product candidate is BNC210. The company was founded in 1996 and is headquartered in Eastwood, Australia.

ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today provides an update to the proposed re-domiciliation of Bionomics to the United States by way of scheme of arrangement between Bionomics and its Shareholders (“Scheme”) as announced on 1 October 2024.

Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement

ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it received a milestone payment of AUS$1M from Carina Biotech for BNC101, one of their partnered legacy oncology programs.

Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program

ADELAIDE, Australia and CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be participating and presenting at the ThinkEquity Conference being held October 30, 2024 at the Mandarin Oriental Hotel in New York, NY.

Bionomics to Present at the ThinkEquity Conference

ADELAIDE, Australia and CAMBRIDGE, Mass., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that the Company has been invited to present at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC, starting Tuesday, October 15th, 2024, at 9:00 a.m. E.T.

Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

ADELAIDE, Australia and CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”), a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system disorders with high unmet medical need, today announced its intention to re-domicile from Australia to the United States via a proposed scheme of arrangement between Bionomics and its shareholders (the “Scheme”) that will be governed by Australian law. Implementation of the Scheme is subject to approval of Bionomics' shareholders as well as regulatory and court approvals.

Bionomics Limited announces intention to re-domicile to the United States

ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be participating and presenting at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 virtually and in-person at the Lotte New York Palace Hotel in New York, NY.

Bionomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

ADELAIDE, Australia and CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced the favorable outcomes of an EoP2 meeting with the FDA, supporting the advancement of its lead asset BNC210 for the treatment of PTSD into Phase 3 based on the positive results of the recently completed Phase 2b ATTUNE study.

Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder

ADELAIDE, Australia and CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will provide a corporate update and discuss the outcomes of an end-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration regarding the advancement of BNC210 for the treatment of post-traumatic stress disorder (PTSD) into Phase 3 on Wednesday, July 31 at 8:00 am ET.

Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024

ADELAIDE, Australia and CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced the initiation of patient screening for the Phase 3 AFFIRM-1 trial evaluating the safety and efficacy of BNC210 for the acute, as-needed treatment of social anxiety disorder (SAD).

Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder

ADELAIDE, Australia and CAMBRIDGE, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”), a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today announced it has entered into a securities purchase agreement with an institutional accredited investor to purchase American Depository Shares (“ADS”) (or pre-funded warrants in lieu thereof) and accompanying warrants in a three-tranche private placement.

Bionomics Limited Announces Private Placement of up to $70.0 Million

ADELAIDE, Australia and CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that Spyridon “Spyros” Papapetropoulos, M.D., PhD, President and Chief Executive Officer of Bionomics will be giving an oral presentation and presenting two posters about BNC210 as a potential treatment for social anxiety disorder and post-traumatic stress disorder (PTSD) at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting taking place May 28 – 31 in Miami Beach, Florida. Details of the presentations are as follows:

Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting

BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications.

Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder

ADELAIDE, Australia and CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be presenting at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 in New York, NY.

Bionomics to Present at the 2024 BIO CEO & Investor Conference

BlackSky Technology

Blade Air Mobility

Cemex SAB de CV

Groupon

Hudbay Minerals

Uranium Energy

Small-cap stocks are particularly vulnerable to higher interest rates. So it's not surprising that many of these stocks are struggling in a higher-for-longer rate environment.

7 Strong Buy Stocks Under $20: February 2024

Positive Phase 2b data announced for BNC210 on reduction of total symptom severity and multiple symptom clusters in post-traumatic stress disorder (PTSD), with a discussion with the U.S. Food & Drug Administration (FDA) anticipated in Q2'24.

Bionomics Provides a Review of 2023 and of 2024 Plans

The Company will provide an update on its leading asset BNC210 and their partnership strategy The Company will provide an update on its leading asset BNC210 and their partnership strategy

Bionomics to Present at Biotech Showcase™ 2024

ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced the presentation of data on the psychometric validity and reliability of SUDS as an outcome measure in assessing anxiety in SAD clinical trials at the 2023 American College of Neuropsychopharmacology Annual Meeting taking place December 3 – 6 in Tampa, Florida.

Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting

ADELAIDE, Australia, and CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced the successful and favorable outcomes of an End-of-Phase 2 meeting (EoP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of its lead asset BNC210 for the acute treatment of Social Anxiety Disorder (SAD) into Phase 3 registrational studies based on the recently completed Phase 2 PREVAIL dataset.

Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder

Planet Labs

ARS Pharmaceuticals Inc

When constructing a watch list of penny stocks, it is wise to closely monitor any legal insider trading activity. Though the rules surrounding insider trades are complex, legal filings by company executives and directors can act like signals for savvy penny stock investors.

Penny Stocks To Buy? 3 That Insiders Are Investing $100,000+ In Now

Bionomics (BNOX) announces positive top-line results from its mid-stage study of BNC210 for the treatment of Post-Traumatic Stress Disorder. The stock of the company rallies 244%.

Bionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244%

Shares of Bionomics Limited rocketed 387% after phase IIb trial results showed its lead asset had the potential to become a best-in-class treatment for post-traumatic stress disorder (PTSD). Researchers found that the drug, BNC210, significantly reduced the severity of PTSD symptoms over a 12-week period.The data also pointed to improvements in related issues like depression and sleep quality.

Bionomics shares soar almost 400% after positive phase IIb results from PTSD treatment

Bionomics (NASDAQ: BNOX ) stock is rocketing higher on Thursday alongside results from a clinical trial. The clinical-stage biotechnology company revealed results from its Phase 2b ATTUNE trial of BNC210.

Why Is Bionomics (BNOX) Stock Up 347% Today?

The stock of microcap Bionomics Ltd. rose 36% early Thursday, after the company reported positive results from a mid-stage trial of a treatment for post-traumatic stress disorder.

Bionomics announces positive results in trial of treatment for PTSD

ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks.

Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today announced an update on the company's α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) collaboration with MSD (known as Merck & Co., Inc., Rahway NJ, USA in the US and Canada). Data for MK-4334, a novel clinical candidate developed by MSD and derived from Bionomics' original α7 nAChR PAM candidate (BNC375), was recently presented at the Society for Chemical Industry (SCI) and Royal Society of Chemistry (RSC) 22nd Medicinal Chemistry Symposium, held in Cambridge, UK, September 10-13, 2023.

News for Bionomics Ltd Stock (BNOX)